Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database
Open Access
- 20 September 2025
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (2) , 515-524
Abstract
Aims: Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends. Methods: ADR reports from the Pharmaceuticals and Medical Devices Agency website, including patient reports from March 2019 to March 2024, and JADER reports from January 2019 to March 2024, were utilized. Information on demographics, drugs, ADR types and outcomes was analysed. Frequencies and comparisons between the two reporting groups were performed. Results: A total of 2913 patient reports and 343 894 JADER reports were analysed. Patients were often younger (30–50 years) and mostly female, whereas JADER reports included older patients (60–80 years) and mostly male. Patients reported subjective symptoms, such as fatigue and headache, often associated with drugs targeting the central nervous system. In contrast, JADER reports focused on serious conditions, such as interstitial lung disease and pneumonia, which are commonly associated with anticancer drugs. Patient and professional ADR reports differed in focus. Patients highlighted quality‐of‐life‐related symptoms, whereas professionals reported more serious medical conditions. Differences in demographics and reporting methods indicate that these systems are complementary. Offering more reporting options, such as telephone‐based submissions, can make the system more inclusive. Conclusions: The study highlights how patient ADR reports provide valuable insights into drug safety. Although differences exist, patient and professional reports improve monitoring after drug approval.Keywords
Funding Information
- Japan Agency for Medical Research and Development (22mk0101228h0001)
This publication has 31 references indexed in Scilit:
- Access to HPV vaccination in Japan: Increasing social trust to regain vaccine confidenceVaccine, 2021
- Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)Pharmacoepidemiology and Drug Safety, 2019
- Reported adverse drug reactions in women and men: Aggregated evidence from globally collected individual case reports during half a centuryeClinicalMedicine, 2019
- Public engagement and the role of the media in post-marketing drug safety: the case of Eltroxin® (levothyroxine) in New ZealandCritical Public Health, 2017
- Patients views and experiences in online reporting adverse drug reactions: findings of a national pilot study in JapanPatient Preference and Adherence, 2015
- Influence of Patient Sex and Gender on Medication Use, Adherence, and Prescribing Alignment with GuidelinesJournal of Women's Health, 2014
- The Metoclopramide Black Box Warning for Tardive Dyskinesia: Effect on Clinical Practice, Adverse Event Reporting, and Prescription Drug LawsuitsAmerican Journal of Gastroenterology, 2013
- Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UKPharmacoepidemiology and Drug Safety, 2011
- Patients’ role in reporting adverse drug reactionsExpert Opinion on Drug Safety, 2004
- Prospective Study of the Influence of the Media on Reporting Medical EventsDrug Information Journal, 1990